| IQV |
Report |
Revenue (Q2'26) |
BEAT |
pred ~$4.34B vs. cons $4.30B |
MEDIUM |
| IQV |
Report |
Adjusted Diluted EPS (Q2'26) |
BEAT |
pred ~$3.08 vs. cons $3.03 |
MEDIUM |
| IQV |
Report |
R&DS book-to-bill (service-fee/TTM) |
MISS |
pred ~1.08x vs. cons ~1.15x |
MEDIUM |
| IQV |
Guide |
FY26 Revenue guide |
BETTER |
guide ~$17.35B vs. cons $17.30B (FY2026, narrow raise) |
LOW |
| IQV |
Guide |
FY26 Adjusted EBITDA guide |
UNCHANGED |
guide ~$4.00B vs. cons $4.00B (FY2026, reaffirm — the disappointment) |
MEDIUM |
| IQV |
Guide |
FY26 Adjusted EPS guide |
BETTER |
guide ~$12.90 vs. cons $12.80 (FY2026, buyback-driven EPS raise) |
MEDIUM |
| IQV |
Guide |
Q3'26 Adj EPS guide |
UNKNOWN |
guide ~$3.20 vs. cons $3.22 (Q3 2026) |
LOW |
| IQV |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| IQV |
Return |
5-day cumulative residual |
-4.5% (FADE) |
Stock is up ~35% since early May and ~28% off June lows into the print, sitting near the top of the $225 analyst target range — priced for a beat-and-raise. Even with a likely revenue/EPS beat, the quality is low: EPS upside is buyback/FX-driven while EBITDA guide is only reaffirmed (not raised) and R&DS book-to-bill likely fails to normalize back to the hoped ~1.15x. Large-pharma decision speed stays 'deliberate,' so out-quarter service-fee revenue conversion gets trimmed and the operational revisions are muted-to-negative even after the headline beat. The out-period math (soft bookings mix + no EBITDA raise) pulls forward estimates down, so the overbought move fades over the week. |
MEDIUM |